Trade News

FDA Determines Semaglutide Injection Shortage Resolved

2025-02-21
FDA Determines Semaglutide Injection Shortage Resolved

FDA confirms semaglutide injection shortage is resolved as manufacturer capacity meets national demand. Other GLP-1 products remain under monitoring.

The U.S. Food and Drug Administration has determined that the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products had been in shortage since 2022 due to increased demand. The FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. However, patients and prescribers may still see intermittent and limited localized supply disruptions as products move through the supply chain. The agency continues to actively monitor the availability of other GLP-1 products including liraglutide injection, which remains in shortage with limited availability across certain presentations.
Read Full Source Article

Hope to become your Partner

Contact us on Telegram for product inquiries, pricing, and orders.

Contact on Telegram
MINSTAR

Shanghai Minstar Chemical Co., Ltd.
RAW API Supplier | Q2 2026 Catalogue.
Shipping from USA and International warehouses.

All products for research use only, not for human or veterinary use, no sales to individuals.

Quick Links

Official Contact

Building 8, No. 1098, Chuansha Road,
Pudong, Shanghai, China

© 2026 Shanghai Minstar Chemical Co., Ltd. All Rights Reserved. | Prices subject to change without notice.